We want to make you aware of some upcoming coverage changes related to Stelara (ustekinumab) and biosimilars. Effective Nov. 1, 2025 for Tufts Health RITogether members, Yesintek will be added to the formulary at a preferred status with prior authorization required, while Stelara and all other FDA-approved biosimilars will be designated as non-preferred, non-formulary.
Patients currently utilizing Stelara will not need a new prior authorization request for Yesintek. However, we strongly recommend that you write a new prescription for Yesintek to make the transition as seamless as possible.
We’ve notified affected members of these changes, as well.